J&J buys Wyeth facility

MARCH 26–NEW YORK–Officials from Johnson & Johnson’s Centocor biomedicines unit say they have agreed to buy a Wyeth manufacturing facility in St. Louis, allowing it to increase production capabilities for its experimental drugs.

The St. Louis facility can produce biologic drugs, or protein-based treatments that are often considered difficult to manufacture.

Terms of the transaction were not disclosed.

The sale comes one day after Wyeth said it would close manufacturing facilities in Marietta, Pennsylvania, cutting 440 jobs.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.